Evaxion Biotech (EVAX) announces business update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Wall Street sinks as bond yields rise, Walmart results disappoint
Evaxion announces business update and first quarter 2025 financial results
May 27, 2025 7:30 AM EDTCOPENHAGEN, Denmark, May 27, 2025 - Evaxion A/S (NASDAQ: EVAX) (Evaxion), a clinical-stage TechBio company specializing in developing AI-Immunology powered vaccines, provides business update and announces first quarter 2025 financial results.
Business highlights (since last quarterly update)
Evaxion has made good progress with continued execution of our strategy and plans. We have achieved the first two milestones for the year and are tracking towards future milestones and value catalysts. Highlights include:
